TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20530392

Group type: EXPERIMENTAL
Intervention: Facilitated group (tailored, intensive assistance and services from TransforMED)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Self-directed group (very limited assistance)
Number of subjects: 36
Study: 17639157

Group type: EXPERIMENTAL
Intervention: 10 g of multimixture added to school meals
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no multimixture)
Number of subjects: 24
Study: 15778243

Group type: EXPERIMENTAL
Intervention: Etanercept treatment for 6 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Etanercept treatment for 24 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 25
Study: 11870097

Group type: EXPERIMENTAL
Intervention: Alternative medicine treatments (specific interventions not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized trials of alternative medicine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Impeccable papers proving absurd claims
Number of subjects: 0
Study: 9704959

Group type: EXPERIMENTAL
Intervention: Immediate postoperative enteral feeding (feeding jejunostomy, low-residue milk-based diet)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no immediate postoperative enteral feeding)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Study group
Number of subjects: 43

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 43
Study: 8726297

Group type: EXPERIMENTAL
Intervention: Mianserin, 120 mg/day
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 1872019

Group type: EXPERIMENTAL
Intervention: Yeast recombinant pre‐S2 + S vaccine (12, 24 or 48 micrograms)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Recombivax HBR (10 micrograms)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Yeast recombinant pre‐S2 + S vaccine
Number of subjects: 104

Group type: COMPARATOR
Intervention: Recombivax HBR
Number of subjects: 104
Study: 7050878

Group type: EXPERIMENTAL
Intervention: 24-gauge Teflon catheter
Number of subjects: 34

Group type: COMPARATOR
Intervention: 25-gauge steel needle
Number of subjects: 34
Study: 31349110

Group type: EXPERIMENTAL
Intervention: BALANCE Program
Number of subjects: 2534

Group type: COMPARATOR
Intervention: Conventional nutrition advice (control group)
Number of subjects: 2534
Study: 29229219

Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (conventional fluoroscopic technique)
Number of subjects: 50
Study: 26950692

Group type: EXPERIMENTAL
Intervention: Psychoanalytic psychotherapy (PPT) for 2 years of weekly sessions
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT) for 5 months
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Psychoanalytic psychotherapy (PPT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 70
Study: 24342121

Group type: EXPERIMENTAL
Intervention: Ringer's acetate (RA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ringer's lactate (RL)
Number of subjects: 80
Study: 22458939

Group type: EXPERIMENTAL
Intervention: AZD9668 60 mg bid
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: AZD9668 5 mg bid
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: AZD9668 20 mg bid
Number of subjects: 838

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 838
Study: 19543000

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: granisetron 1 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 90
Study: 17380590

Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg, 40 mg, and 60 mg single doses
Number of subjects: 88

Group type: COMPARATOR
Intervention: Duloxetine 20 mg and 40 mg twice-daily for 5 days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 15450676

Group type: EXPERIMENTAL
Intervention: Topiramate (50 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ketamine (0.12 mg bolus followed by 0.5 mg/kg over 60 min)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 36
Study: 11408234

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg intravenous
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9818104

Group type: EXPERIMENTAL
Intervention: 5-HT2 antagonist (sarpogrelate hydrochloride, 300 mg a day po)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Repeated stellate ganglion blocks (SGBs) with mepivacaine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combined therapy (5-HT2 antagonist with SGBs)
Number of subjects: 33
Study: 9006217

Group type: EXPERIMENTAL
Intervention: Individualized feedback counselling (1 or 2 sessions of 15-30 minutes each, including supervised testing and error correction)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no individualized feedback counselling)
Number of subjects: 71
Study: 2506490

Group type: EXPERIMENTAL
Intervention: 10% lipidic emulsion based on safflower oil and soya (Liposyn II)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10% Intralipid
Number of subjects: 20
Study: 772172

Group type: EXPERIMENTAL
Intervention: Thioridazine treatment (n=23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo treatment (n=22)
Number of subjects: 45
Study: 31947853

Group type: EXPERIMENTAL
Intervention: Isomaltulose (50 g)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sucrose (50 g)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isomaltulose
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 80
Study: 30844048

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Non-febuxostat (conventional therapy with lifestyle modification)
Number of subjects: 1070
Study: 28709022

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy skills-based intervention
Number of subjects: 93

Group type: COMPARATOR
Intervention: Relaxation training control condition
Number of subjects: 93
Study: 25883166

Group type: EXPERIMENTAL
Intervention: InsuPad device
Number of subjects: 14

Group type: COMPARATOR
Intervention: No InsuPad device (control)
Number of subjects: 14
Study: 22732180

Group type: EXPERIMENTAL
Intervention: L-arginine (9 g daily for 6 months)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 88
Study: 21167859

Group type: EXPERIMENTAL
Intervention: HB‐AS02 vaccine (two doses given one month apart)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Licensed conventional recombinant hepatitis B vaccine (HBVAXPRO™; two doses)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: HB‐AS02 vaccine (single booster dose)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Licensed conventional recombinant hepatitis B vaccine (single booster dose)
Number of subjects: 432
Study: 18042311

Group type: EXPERIMENTAL
Intervention: Once-monthly ibandronate 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly alendronate 70 mg
Number of subjects: 0
Study: 16879331

Group type: EXPERIMENTAL
Intervention: High-speed handpiece + 37% phosphoric acid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (350 mJ, 4 Hz and 112 J/cm(2)) + 37% phosphoric acid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (350 mJ, 4 Hz and 112 J/cm(2)) + Er:YAG laser (80 mJ, 4 Hz, and 25 mJ/cm(2))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Er:YAG laser preparation
Number of subjects: 30
Study: 14708420

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oxybutinin (0.4 mg/kg)
Number of subjects: 24
Study: 11179910

Group type: EXPERIMENTAL
Intervention: Triptorelin alone (arm A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Triptorelin with formestane (arm B)
Number of subjects: 21
Study: 9310809

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-clonidine treatment
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Clonidine treatment
Number of subjects: 27
Study: 8311748

Group type: EXPERIMENTAL
Intervention: Mitral valve replacement with preservation of posterior leaflet and chordae tendineae (group 1)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional mitral valve replacement (group 2)
Number of subjects: 21
Study: 3753293

Group type: EXPERIMENTAL
Intervention: Oral calcium antagonist (nifedipine)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous naftidrofuryl with vitamin A, vitamin E, and zinc
Number of subjects: 50
Study: 30256884

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 1
Study: 26588809

Group type: EXPERIMENTAL
Intervention: 5 g transdermal testosterone gel (TT) (N = 16)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Anastrozole (AI) 1 mg (N = 14)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (N = 13)
Number of subjects: 43
Study: 24695894

Group type: EXPERIMENTAL
Intervention: In-store marketing intervention for 6 months promoting healthier products through placement, signage, and product availability strategies.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group with no intervention (assessment-only).
Number of subjects: 8
Study: 23171568

Group type: EXPERIMENTAL
Intervention: Multidisciplinary collaboration program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 19851858

Group type: EXPERIMENTAL
Intervention: Dose-intensive neoadjuvant therapy
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Clonal hematopoiesis assays
Number of subjects: 274
Study: 17941031

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (CT) screening for lung cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simulated control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT screening
Number of subjects: 0
Study: 16188549

Group type: EXPERIMENTAL
Intervention: Bone morphogenetic proteins (BMPs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapy using BMPs
Number of subjects: 0
Study: 11861035

Group type: EXPERIMENTAL
Intervention: 1 mg 17 beta-estradiol continuously plus sequential progestagen over 1 year
Number of subjects: 51

Group type: COMPARATOR
Intervention: Discontinuation of HRT after 12 months
Number of subjects: 51
Study: 10439739

Group type: EXPERIMENTAL
Intervention: methohexital-desflurane
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: methohexital-sevoflurane
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: propofol-desflurane
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: propofol-sevoflurane
Number of subjects: 120
Study: 9732842

Group type: EXPERIMENTAL
Intervention: Acetylation phenotype and smoking
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no acetylation phenotype or smoking)
Number of subjects: 76
Study: 2699100

Group type: EXPERIMENTAL
Intervention: F XIII concentrate treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-treated group
Number of subjects: 56
Study: 30557370

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 368
Study: 28473136

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 2604

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2604
Study: 24081439

Group type: EXPERIMENTAL
Intervention: High dose fish oil (5.5 g/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (low dose fish oil 0.4 g/day)
Number of subjects: 60
Study: 23318484

Group type: EXPERIMENTAL
Intervention: P/MC (sodium picosulfate and magnesium citrate)
Number of subjects: 603

Group type: COMPARATOR
Intervention: 2L PEG‐3350 and bisacodyl tablets
Number of subjects: 603
Study: 21247461

Group type: COMPARATOR
Intervention: Hospital management
Number of subjects: 240

Group type: COMPARATOR
Intervention: Home management
Number of subjects: 240
Study: 19531579

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Bucindolol
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study: 16505266

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Minimal Acupuncture
Number of subjects: 298

Group type: COMPARATOR
Intervention: Waiting List Control
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Acupuncture vs Minimal Acupuncture
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Acupuncture vs Waiting List Control
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Acupuncture vs Minimal Acupuncture at 26 weeks
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Acupuncture vs Minimal Acupuncture at 52 weeks
Number of subjects: 298
Study: 15482502

Group type: EXPERIMENTAL
Intervention: Social communication intervention with regular monthly therapist contact for 6 months and 2-monthly consolidation sessions for an additional 6 months.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Social communication intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 28
Study: 11058002

Group type: EXPERIMENTAL
Intervention: Trapeziectomy with ligament reconstruction and tendon interposition (LRTI)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Trapeziectomy alone (control)
Number of subjects: 43
Study: 9274584

Group type: EXPERIMENTAL
Intervention: Ivermectin plus Albendazole (200-400 micrograms/kg ivermectin and 400 mg albendazole)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Ivermectin alone (200-400 micrograms/kg, mean 273 micrograms/kg)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Albendazole alone (400 mg)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 8384733

Group type: EXPERIMENTAL
Intervention: Oral vaccine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Subcutaneous vaccine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Typhoid fever patients
Number of subjects: 15
Study: 3105886

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pentazocine (Control)
Number of subjects: 10
Study: 31255456

Group type: EXPERIMENTAL
Intervention: Biportal endoscopic unilateral laminotomy bilateral decompression
Number of subjects: 89

Group type: COMPARATOR
Intervention: Microscopic unilateral laminotomy bilateral decompression
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Biportal endoscopic surgery
Number of subjects: 89
Study: 28836120

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention (MDI)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Brief intervention (BI)
Number of subjects: 168
Study: 27373358

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.3 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline (placebo) 2 ml
Number of subjects: 100
Study: 25122671

Group type: EXPERIMENTAL
Intervention: Masitinib (12 mg/kg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sunitinib (50 mg/day 4-weeks-on/2-weeks-off)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Masitinib
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 44
Study: 22989021

Group type: EXPERIMENTAL
Intervention: Systematic Activation Method (SAM)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 102
Study: 20863554

Group type: COMPARATOR
Intervention: Cisplatin 50 mg/m² + Doxorubicin 45 mg/m² + G‐CSF 5 μg/kg (CD)
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m² + Doxorubicin 45 mg/m² + G‐CSF 5 μg/kg + Paclitaxel 160 mg/m² (CDP)
Number of subjects: 552
Study: 18508824

Group type: EXPERIMENTAL
Intervention: Cell phone-based exercise programme (daily endurance walking at 80% of maximal capacity, adjusted monthly based on ISWT results)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cell phone-based exercise programme
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (verbal instructions for daily walking exercise at home)
Number of subjects: 48
Study: 17265571

Group type: EXPERIMENTAL
Intervention: etoricoxib (≥ 60 mg/day)
Number of subjects: 6500

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6500

Group type: COMPARATOR
Intervention: non-naproxen traditional NSAIDs (ibuprofen and diclofenac)
Number of subjects: 6500

Group type: COMPARATOR
Intervention: naproxen (1000 mg/day)
Number of subjects: 6500
Study: 14635505

Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 9
Study: 10868999

Group type: EXPERIMENTAL
Intervention: Prednisone for two months
Number of subjects: 868

Group type: COMPARATOR
Intervention: Prednisone for three months or more
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Prednisone for longer durations (up to seven months)
Number of subjects: 868
Study: 9063785

Group type: EXPERIMENTAL
Intervention: Oral ketamine
Number of subjects: 19

Group type: COMPARATOR
Intervention: 300 mg acetaminophen with codeine phosphate and diphenhydramine
Number of subjects: 19
Study: 8240534

Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole gel
Number of subjects: 51

Group type: COMPARATOR
Intervention: Excipient (placebo)
Number of subjects: 51
Study: 2425961

Group type: EXPERIMENTAL
Intervention: S-Adenosyl methionine (SAM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31955013

Group type: EXPERIMENTAL
Intervention: Ad libitum TRF
Number of subjects: 23

Group type: COMPARATOR
Intervention: Isocaloric TRF
Number of subjects: 23
Study: 30716452

Group type: EXPERIMENTAL
Intervention: Fiber posts (Subgroup A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No fiber posts (Subgroup B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fiber posts in molars (Group 2A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tooth type (premolars vs molars)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Presence of post
Number of subjects: 60
Study: 28852276

Group type: EXPERIMENTAL
Intervention: Peer-led intervention
Number of subjects: 824

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 824
Study: 25479584

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/d
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study: 23265352

Group type: EXPERIMENTAL
Intervention: L-DOPS co-administered with entacapone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Entacapone alone
Number of subjects: 16

Group type: COMPARATOR
Intervention: L-DOPS alone
Number of subjects: 16
Study: 21303529

Group type: EXPERIMENTAL
Intervention: Preventive spinal manipulative therapy (SMT) - 1 monthly session for 10 months
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Preventive spinal manipulative therapy with home exercise program (SMT + exercise) - 1 monthly SMT session combined with home exercises for 10 months
Number of subjects: 98

Group type: COMPARATOR
Intervention: Attention-control group - meeting with a chiropractor every two months for 10 months
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: All groups (SMT, SMT + exercise, attention-control)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Preventive phase of the trial
Number of subjects: 98
Study: 19673707

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Acetaminophen/Hydrocodone (650 mg acetaminophen with 10 mg hydrocodone)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (800 mg of lactose)
Number of subjects: 25
Study: 16430622

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg once daily
Number of subjects: 8113

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 8113
Study: 15008832

Group type: EXPERIMENTAL
Intervention: Euglycaemia with alcohol
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia with alcohol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Hypoglycaemia without alcohol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Euglycaemia with placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: Hypoglycaemia with placebo
Number of subjects: 17
Study: 11482747

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice daily for up to 12 months
Number of subjects: 714
Study: 9444018

Group type: EXPERIMENTAL
Intervention: Praziquantel 5 mg/kg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Praziquantel 2.5 mg/kg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Mebendazole 800 mg in 10d table salt
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Mebendazole 400 mg in 10d table salt
Number of subjects: 109
Study: 7962320

Group type: EXPERIMENTAL
Intervention: Lo/Ovral
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ovral
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (never used OCs or discontinued for at least 24 months)
Number of subjects: 0
Study: 3454918

Group type: EXPERIMENTAL
Intervention: Oscillation frequencies of 1, 2, 3, 5, 8, 13 and 20 Hz
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Age groups (20-23, 40-55, 60-80)
Number of subjects: 30
Study: 29199013

Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% once daily (q.d.)
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% twice daily (b.i.d.)
Number of subjects: 1167

Group type: COMPARATOR
Intervention: Timolol 0.5% twice a day (b.i.d.)
Number of subjects: 1167
Study: 27397838

Group type: EXPERIMENTAL
Intervention: Evidence-based practice education (4-hour live sessions + web-based module + mentoring)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Research utilization education (4-hour live sessions)
Number of subjects: 85
Study: 24342252

Group type: EXPERIMENTAL
Intervention: Alternate dosing schedule (0, 2, 12 months)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard dosing schedule (0, 2, 6 months)
Number of subjects: 220